Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) Short Interest Down 24.9% in January

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) was the target of a large drop in short interest in the month of January. As of January 30th, there was short interest totaling 144,124 shares, a drop of 24.9% from the January 15th total of 192,015 shares. Based on an average daily volume of 181,961 shares, the days-to-cover ratio is currently 0.8 days. Currently, 1.0% of the company’s shares are sold short. Currently, 1.0% of the company’s shares are sold short. Based on an average daily volume of 181,961 shares, the days-to-cover ratio is currently 0.8 days.

Wall Street Analyst Weigh In

Separately, D. Boral Capital reiterated a “buy” rating and issued a $9.00 target price on shares of Kairos Pharma in a report on Wednesday, November 19th. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $8.33.

Kairos Pharma Trading Up 0.7%

NYSEAMERICAN:KAPA opened at $0.60 on Tuesday. The business’s fifty day moving average price is $0.75 and its 200 day moving average price is $1.00. The firm has a market capitalization of $12.45 million, a price-to-earnings ratio of -1.93 and a beta of 2.28. Kairos Pharma has a 1-year low of $0.40 and a 1-year high of $2.11.

Kairos Pharma (NYSEAMERICAN:KAPA) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.07) EPS for the quarter.

Institutional Investors Weigh In On Kairos Pharma

Institutional investors have recently modified their holdings of the stock. XTX Topco Ltd purchased a new position in shares of Kairos Pharma during the 2nd quarter valued at $44,000. Two Sigma Investments LP purchased a new position in Kairos Pharma in the third quarter valued at about $54,000. Finally, FNY Investment Advisers LLC acquired a new position in Kairos Pharma in the 3rd quarter worth about $27,000.

Kairos Pharma Company Profile

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.